M-A | Cardiovascular and venous thromboembolic risk with Janus Kinase inhibitors in immune-mediated inflammatory diseases. 1 Aug, 2022 | 11:52h | UTC Cardiovascular and Venous Thromboembolic Risk With Janus Kinase Inhibitors in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis of Randomized Trials – ACR Open Rheumatology